{"nctId":"NCT00127166","briefTitle":"Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911)","startDateStruct":{"date":"2005-12"},"conditions":["Exercise Induced Asthma"],"count":154,"armGroups":[{"label":"Montelukast/Salmeterol","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast sodium","Drug: Salmeterol xinafoate","Drug: Fluticasone propionate","Drug: Montelukast matching placebo","Drug: Salmeterol matching placebo"]},{"label":"Salmeterol/Montelukast","type":"EXPERIMENTAL","interventionNames":["Drug: Montelukast sodium","Drug: Salmeterol xinafoate","Drug: Fluticasone propionate","Drug: Montelukast matching placebo","Drug: Salmeterol matching placebo"]}],"interventions":[{"name":"Montelukast sodium","otherNames":[]},{"name":"Salmeterol xinafoate","otherNames":[]},{"name":"Fluticasone propionate","otherNames":[]},{"name":"Montelukast matching placebo","otherNames":[]},{"name":"Salmeterol matching placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* 6-14 year old children with a history of asthma for at least 12 months\n* must demonstrate airway constriction brought on by exercise\n\nExclusion Criteria:\n\n* is taking any medications that are not allowed in the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Years","maximumAge":"14 Years","stdAges":["CHILD"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Maximum Post-exercise Percent (%) Fall in FEV1","description":"The effect of four weeks of treatment with oral montelukast plus inhaled fluticasone, and inhaled salmeterol plus inhaled fluticasone on EIB as measured by the maximum post-exercise percent fall (relative to pre-exercise baseline) in FEV1.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.57","spread":null},{"groupId":"OG001","value":"13.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Curve for %-Change From Pre-exercise Baseline FEV1 in Liters (L), From 0 to 20 Minutes (AUC(0-20))","description":"The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the area under the curve from 0 to 20 minutes (AUC0-20) for FEV1 percent change from pre-exercise baseline.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"116.04","spread":null},{"groupId":"OG001","value":"168.75","spread":null}]}]}]},{"type":"SECONDARY","title":"Maximum FEV1 % Predicted Following First Beta-agonist Use","description":"The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on short-acting β-agonist bronchodilation as measured by the maximum FEV1 percent predicted following first β-agonist use.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"104.03","spread":null},{"groupId":"OG001","value":"99.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Time to Recovery to Within 5% of Baseline FEV1","description":"The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the time to recovery (to within 5 percent of the pre-exercise baseline FEV1) following a standardized exercise challenge.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"11.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Average (Avg) %-Change in FEV1 After First Beta (β)-Agonist Use and Prior to Second β-agonist Use","description":"The effect of a four-week treatment course of oral montelukast plus inhaled fluticasone, compared to inhaled salmeterol plus inhaled fluticasone, on the extent and severity of EIB as measured by the average percent change in FEV1 after first β-agonist intake and prior to second β-agonist use.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.51","spread":null},{"groupId":"OG001","value":"2.72","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":150},"commonTop":["Pharyngitis","Asthma","Tonsillitis","Nasopharyngitis","Diarrhoea"]}}}